HOUSTON, Texas — Cellenkos®, Inc., a clinical stage biotechnology company, pioneering allogeneic, tissue-targeted regulatory T cell (Treg) therapies, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug application to initiate a Phase 1b/ 2a clinical trial of CK0802 for the treatment of patients with steroid-refractory...
treatment News
ORANGE, Calif. — Today, the Center for Inherited Blood Disorders (CIBD) announced the successful administration of the first gene therapy infusion in the country to treat hemophilia A outside of the clinical trial setting. The landmark infusion, administered by CIBD’s skilled medical team, is a testament to the center’s commitment...
HOPEWELL, N.J. – Capital Health’s Center for Neuro-Oncology, part of Capital Institute for Neurosciences and the Capital Health Cancer Center, continues to demonstrate nationally the program’s leadership and commitment to clinical excellence. Over the last month, the center’s neurosurgical director, Navid Redjal, MD, FAANS, led publication of guidelines for the treatment...
CAMBRIDGE, Mass. and BERLIN, Germany — Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the Company reached its initial recruitment and genetic testing milestone in the observational EFRONT Study, being conducted to advance the genetic understanding of frontotemporal dementia...
TORONTO, Canada – CAMH-led pre-clinical studies using a small molecule drug have shown promise as a potential new treatment for multiple sclerosis (MS). The results have been published today in the journal Science Advances. Expanding on Dr. Fang Liu’s earlier work that identified a novel drug target for the treatment...
FRAZER, Pa. — Cephalon, Inc. (Nasdaq: CEPH) today announced results from a pivotal clinical trial of lestaurtinib (CEP-701) in patients with relapsed acute myelogenous leukemia (AML) expressing FLT3 activating mutations. The study was designed to show the benefit of lestaurtinib in this patient population when given in sequence with standard...
SUNNYVALE, Calif. — Cepheid (Nasdaq: CPHD) today announced the release of its improved Xpert(R) BCR-ABL Monitor test to be marketed as a CE IVD product under the European Directive on In Vitro Diagnostic Medical Devices. With improved time-to-results, the test now detects the BCR-ABL chromosomal translocation in about 2 hours...
SAN DIEGO — Ceregene, Inc. today reported additional clinical data from a double-blind, controlled Phase 2 trial of CERE-120 in 58 patients with advanced Parkinson’s disease. CERE-120 uses AAV-based gene therapy to deliver the neurotrophic factor, neurturin, to Parkinson’s disease patients in order to restore the function and protect degenerating...
Gothenburg, Sweden – Cereno Scientific (Nasdaq First North: CRNO B), a biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today reported further analyses from the 12-month Expanded Access Program (EAP) with its lead drug candidate CS1 in pulmonary arterial hypertension (PAH). Over...
SAN CARLOS, Calif. — Cerepeut, Inc., a biotechnology company developing mitochondrial therapeutics for neurodegenerative disease, today announced publication of a landmark study in Neuron revealing why the brain turns on itself in Alzheimer’s disease and related disorders, and unveiling a drug candidate designed to stop it. Tau is a well-known driver...